The extra-hematopoietic role of erythropoietin in diabetes mellitus

Current Diabetes Reviews

Volumn 7, Issue 4, 2011, Pages 284-290

  Choi, Diana ^a   Retnakaran, Ravi ^b,c   Woo, Minna ^a,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Angiogenesis; Apoptosis; Diabetes; Erythropoietin; Pancreatic cell; Rhuepo

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANGIOGENESIS; APOPTOSIS; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG MECHANISM; ENDOTHELIUM CELL; ERYTHROCYTOSIS; GLYCEMIC CONTROL; HEART; HUMAN; INSULIN SENSITIVITY; KIDNEY; KIDNEY DISEASE; METABOLISM; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENERGY METABOLISM; ERYTHROPOIETIN; HEMATOPOIETIC SYSTEM; HUMANS; MODELS, BIOLOGICAL;

EID: 79960972169     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339911796397820     Document Type: Review

References (114)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the preva-lence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
3. Eisenbarth GS, Nayak RC, Rabinowe SL. Type 1 diabetes as a chronic autoimmune disease. J Diabet Complications 1988; 2: 54-8.
4. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
5. McCarthy MI, Zeggini E. Genome-wide association studies in type 2 diabetes. Curr Diab Rep 2009; 9: 164-71.
6. Carnot P, Deflandre C. Sur l'activite hemopoietique de serum au cours de la regeneration du sang. C R Acad Sci 1906; 143: 384-6.
7. Carnot P, Deflandre C. Sur l'activite hemopoietique des different organs au cours de la regeneration du sang. C R Acad Sci 1906; 143: 432-5.
8. Bachmann S, Le Hir M, Eckardt KU. Co-localization of erythro-poietin mRNA and ecto-5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 1993; 41: 335-41.
9. Bondurant MC, Koury MJ. Anemia induces accumulation of erythropoietin mRNA in the kidney and liver. Mol Cell Biol 1986; 6: 2731-3.
10. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003; 228: 1-14.
11. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and charac-terization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806-10.
12. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985; 82: 7580-4.
13. Adamson JW, Eschbach JW. Treatment of the anemia of chronic renal failure with recombinant human erythropoietin. Annu Rev Med 1990; 41: 349-60.
14. Abels RI, Larholt KM, Krantz KD, Bryant EC. Recombinant hu-man erythropoietin (rHuEPO) for the treatment of the anemia of cancer. The Oncologist 1996; 1: 140-50.
15. Laupacis A, Fergusson D. Erythropoietin to minimize perioperative blood transfusion: a systemic review of randomized trials. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Transfus Med 1998; 8: 304-17.
16. Garcia JF, Ebbe SN, Hollander L, Cutting HO, Miller ME, Cronkite EP. Radioimmunoassay of erythropoietin: circulating levels in normal and polycythemic human beings. J Lab Clin Med 1982; 99: 624-35.
17. Tan CC, Eckardt KU, Ratcliffe PJ. Organ distribution of erythro-poietin mRNA in the kidney and liver. Kidney Int 1991; 40: 69-76.
18. Tan CC, Eckardt KU, Firth JD, Ratcliffe PJ. Feed-back modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol 1992; 263: F474-81.
19. Yamamoto Y, Sofikitis N, Miyagawa I. Effects of erythropoietin, bromocryptine and hydralazine on testicular function in rats with chronic renal failure. Andrologia 1997; 29: 141-4.
20. Chikuma M, Masuda S, Kobayashi T, Nagao M, Sasaki R. Tissue-specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am J Physiol Endocrinol Metab 2000; 279: E1242-8
21. Rundqvist H, Sundberg CJ, Rullman E, et al. Erythropoietin and its receptor in human skeletal muscle. FASEB J 2007; 21: 767.
22. Erslev AJ, Caro J, Kansu E, Silver R. Renal and extrarenal erythro-poietin production in anaemia. Br J Haematol 2008; 45: 65-72.
23. Wen D, Boissel JP, Showers M, Ruch BC, Bunn HF. J Biol Chem 1994; 269: 22839-46.
24. Constantinescu SN, Ghaffari S, Lodish HF. The erythropoietin receptor: structure, activation and intracellular signal transduction. Trends Endocrinol Metab 1999; 10: 18-23.
25. Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999; 253: 143-56.
26. Damen JE, Wakan H, Miyajima A, et al. Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and stat5 activation. EMBO J 1995; 14: 5557-68.
27. Damen JE, Cutler RL, Jiao H, Yi T, Krystal G. Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the p85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity. J Biol Chem 1995; 270: 23402-8.
28. Damen JE, Liu L, Cutler RL, Krystal G. Erythropoietin stimulates the tyrosine phosphorylation of Shc and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein. Blood 1993; 82: 2296-303.
29. Bittorf T, Seiler J, Ludtke B, Buchse T, Jaster R, Brock J. Activa-tion of STAT5 during EPO-directed suppression of apoptosis. Cell Signal 2000; 12: 23-30.
30. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6: 484-94.
31. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 2003; 26: 1164-9.
32. Thomas MC. The high prevalence of anemia in diabetes is linked to functional erythropoietin deficiency. Semin Nephrol 2006; 26: 275-82.
33. McGill JB, Bell DS. Anemia and the role of erythropoietin in dia-betes. J Diabetes Complications 2006; 20: 262-72.
34. Thomas MC, Cooper ME, Rossing K, Parving HH. Anaemia in diabetes: is there a rationale to TREAT? Diabetologia 2006; 49: 1151-7.
35. Craig KJ, Williams JD, Riley SG, et al. Anemia and diabetes in the absence of nephropathy. Diabetes Care 2005; 28: 1118-23.
36. Thomas MC, Cooper ME, Tsalamandris C, MacIsaac R, Jerums G. Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 2005; 165: 466-9.
37. Mojiminiyi OA, Abdella NA, Zaki MY, El Gebely SA, Mohamedi HM, Aldhahi WA. Prevalence and associations of low plasma erythropoietin in patients with type 2 diabetes mellitus. Diabet Med 2006; 23: 839-44.
38. Winkler AS, Marsden J, Chaudhuri KR, Hambley H, Watkins PJ. Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med 1999; 16: 813-9.
39. Tascona DJ, Morton AR, Toffelmire EB, Holland DC, Iliescu EA. Adequacy of glycemic control in hemodialysis patients with diabetes. Diabetes Care 2006; 29: 2247-51.
40. Khedr E, El-Sharkawy M, Abdulwahab S, et al. Effect of recombi-nant human erythropoietin on insulin resistance in hemodialysis patients. Hemodialysis Int 2009; 13: 340-6.
41. Stefanovic V, Nesic V, Stojimirovic B. Treatment of insulin resis-tance in uremia. Int J Artif Organs 2003; 26: 100-4.
42. Tuzcu A, Bahceci M, Yilmaz E, Bahceci S, Tuzcu S. The compare-son of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin. Horm Metab Res 2004; 36: 716-20.
43. Mak RH. Metabolic effects of erythropoietin in patients on perito-neal dialysis. Pediatr Nephrol 1998; 12: 660-5.
44. Chagnac A, Weinstein T, Zevin D, et al. Effect of erythropoietin on glucose tolerance in hemodialysis patients. Clin Nephrol 1994; 42: 398-400.
45. Spaia S, Pangalos M, Askepidis N, et al. Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron 2000; 84: 320-5.
46. Stefanovic V, Antic S. Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus. Clin Lab 2004; 50: 271-8.
47. Maddux BA, Sbraccia P, Kumakura S, et al. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature 1995; 373: 448-51.
48. Maddux BA, Chang YN, Accili D, Mcguinness OP, Youngren JF, Goldfine ID. Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemia. Am J Physiol Endocrinol Metab 2006; 290: E746-9.
49. Allegra V, Mengozzi G, Martimbianco L, Vasile A. Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients. Am J Nephrol 1996; 16: 304-8.
50. Mak RH. Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia. J Pediatr 1996; 129: 97-104.
51. Kristensen PL, Hoi-Hansen T, Olsen NV, Pedersen-Bjergaard U, Thorsteinsson B. Erythropoietin during hypoglycaemia in type 1 diabetes: relation to basal renin-angiotensin system activity and cognitive function. Diab Res Clin Pract 2009; 85: 75-84.
52. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglo-bin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-84.
53. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or erythropoietin receptor. Cell 1995; 83: 59-67.
54. Suzuki N, Ohneda O, Takahashi S, et al. Erythroid-specific expres-sion of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002; 100: 2279-88.
55. Wu H, Lee SH, Gao J, Lin X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999; 126: 3597-605.
56. Yu X, Shacka JJ, Eells JB, et al. Erythropoietin receptor signaling is required for normal brain development. Development 2002; 129: 505-16.
57. Tsai PT, Ohab JJ, Kertesz N, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 2006; 26: 1269-74.
58. Juul SE, Joyce AE, Zhao Y, Ledbetter DJ. Why is erythropoietin present in human milk? Studies of erythropoietin receptors on enterocytes of human and rat neonates. Pediatr Res 1999; 46: 263-8.
59. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998; 273: 25381-25387.
60. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells expression functional erythropoietin receptors. Kidney Int 1999; 55: 808-20.
61. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 1990; 87: 5978-82.
62. Fenjves ES, Ochoa MS, Cabrera O, et al. Human, nonhuman pri-mate, and rat pancreatic islets express erythropoietin receptors. Transplantation 2003; 75: 1356-60.
63. Brines M, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000; 97: 10526-31.
64. Kaptanoglu E, Solaroglu I, Okutan O, Surucu HS, Akbiyik F, Beskonakli E. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidatino and early ultrastructural findings. Neurosurgical Rev 2004; 27: 113-20.
65. Savino C, Pedotti R, Baggi F, et al. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neurol 2006; 172: 27-37.
66. Grunfeld JF, Barhum Y, Blondheim N, Rabey JM, Melamed E Offen D. Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Exp Neurol 2007; 204: 260-3.
67. Studer L, Csete M, Lee SH, et al. Enhanced proliferation, survival and dopaminergic differentiation of CNS precursors in lowered oxygen. J Neurosci 2000; 20: 7377-83.
68. Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regu-lates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001; 21: 9733-43.
69. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004; 35: 1732-1737.
70. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 495-505.
71. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-5.
72. Silverberg DS, Wexler D, Blum M. The effect of correction of anemia in diabetics and non-diabetics with severe resistance con-gestive heart failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18: 141-6.
73. Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myo-cardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A 2003; 100: 11612-7.
74. Van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin im-proves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail 2004; 6: 853-9.
75. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocyte associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004; 18: 1031-3.
76. Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab 2003; 23: 320-30.
77. Chong ZZ, Kang JQ, Maiese K. Angiogenesis and plasticity: a role of erythropoietin in vascular systems. J Hematother Stem Cell Res 2002; 11: 863-71.
78. Galeano M, Altavilla D, Cucinotta D, et al. Recombinant Human Erythropoietin stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetes 2004; 53: 2509-17.
79. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythro-poietin as an angiogenic factor. Eur J Clin Invest 2003; 33: 891-6.
80. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythro-poietin stimulates angiogenesis in vitro. Kidney Int 1995; 47: 740-745.
81. Chong ZZ, Kang JQ, Maise K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106: 2973-9.
82. Santhanam AV, Smith LA, Akiyama M, Rosales AG, Bailey KR, Katusic ZS. Role of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 2005; 36: 2731-7.
83. Satoh K, Kagaya Y, Nakano M, et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006; 113: 1442-50.
84. Urao N, Okigaki M, Yamada H, et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Aktendothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 2006; 98: 1405-13.
85. Chatterjee PK. Pleiotropic renal actions of erythropoietin. Lancet 2005; 365: 1890-2.
86. Fenjves ES, Ochoa MS, Gay-Ravinstein C, et al. Adenoviral gene transfer of erythropoietin confers cytoprotection to isolated pancreatic islets. Transplantation 2004; 77: 13-8.
87. Choi D, Schroer SA, Lu SY, et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med 2010; 207: 2831-42.
88. Katz O, Stuible M, Golishevski N, et al. Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol 2010; 5: 87-95.
89. Kim H, Rafiuddin-Shah M, Tu HC, et al. Hierarchical regulation of mitochondrion-dependent apoptosis by Bcl-2 subfamilies. Nat Cell Biol 2006; 8: 1348-58.
90. Silva M, Benito A, Sanz C, et al. Erythropoietin can induce the expression of Bcl-xL through stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 1999; 274: 22165-9.
91. Bouscary D, Pene F, Claessens YE, et al. Critical role for PI3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 2003; 101: 3436-43.
92. Brun T, Franklin I, St-Onge L, et al. The diabetes-linked transcript-tion factor PAX4 promotes beta-cell proliferation and survival in rat and human islets. J Cell Biol 2004; 167: 1123-35.
93. Kushner JA, Ciemerych MA, Sicinska E, et al. Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. Mol Cell Biol 2005; 25: 3752-62.
94. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeiffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998; 93: 397-409.
95. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385-95.
96. Zhuang H, Niu Z, He T-C, Patel SV, Wojchowski DM. Erythro-poietin-dependent inhibition of apoptosis is supported by carboxyltruncated receptor forms and blocked by dominant-negative forms of Jak2. J Biol Chem 1995; 270: 14500-4.
97. Cousin SP, Hugl SR, Myers MG Jr, White MF, Reifel-Miller A, Rhodes CJ. Stimulation of pancreatic beta-cell proliferation by growth hormone is glucose-dependent: signal transduction via janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) with no crosstalk to insulin receptor substratemediated mitogenic signalling. Biochem J 1999; 344: 649-58.
98. Fujinaka Y, Takane K, Yamashita H, Vasavada RC. Lactogens promote beta cell survival through JAK2/STAT5 activation and Bcl-L upregulation. J Biol Chem 2007; 282: 30707-17.
99. Liu JL, Coschigano KT, Robertson K, et al. Disruption of growth hormone receptor gene causes diminished pancreatic islet size and increased insulin sensitivity in mice. Am J Phyiol Endocrinol Metab 2004; 287: E405-13.
100. Freemark M, Avril I, Fleenor D, et al. Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance. Endocrinology 2002; 143: 1378-85.
101. Lee JY, Gavrilova O, Davani B, Robinson GW, Hennighausen L. The transcription factors Stat5a/b are not required for islet development but modulate pancreatic beta-cell physiology upon aging. Biochim Biophys Acta 2007; 1773: 1455-61.
102. Jackerott M, Moldrup A, Thams P, et al. STAT5 activity in pancre-atic beta-cells influences the severity of diabetes in animal models of type 1 and type 2 diabetes. Diabetes 2006; 55: 2705-12.
103. Lifson N, Lassa CV, Dixit PK. Relation between blood flow and morphology in islet organ of rat pancreas. Am J Physiol 1985; 249: E43-8.
104. Murakami T, Miyake T, Tsubouchi M, Tsubouchi Y, Ohtsuka A, Fujita T. Blood flow patterns in the rat pancreas: a simulative demonstration by injection replication and scanning electron microscopy. Miscrosc Res Tech 1997; 37: 497-508.
105. Bearer EL, Orci L. Endothelial fenestral diaphragms: a quick-freeze, deep-etch study. J Cell Biol 1985; 100: 418-28.
106. Carlsson PO, Liss P, Andersson A, Jansson L. Measurements of oxygen tension in native and transplanted rat pancreatic islets. Diabetes 1998; 47: 1027-32.
107. Brissova M, Shostak A, Shiota M, et al. Pancreatic islet production of vascular endothelial growth factor-A is essential for islet vascularization, revascularization, and function. Diabetes 2006; 55: 2974-85.
108. Lammert E, Gu G, McLaughlin M, et al. Role of VEGF-A in vas-cularization of pancreatic islets. Curr Biol 2003; 13: 1070-4.
109. Rundqvist H, Rullman E, Sundberg CJ, et al. Activation of the erythropoietin receptor in human skeletal muscle. Eur J Endocrinol 2009; 161: 427-34.
110. Hojman P, Brolin C, Gissel H, et al. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS ONE 2009; 4: e5894.
111. Kobayashi K, Forte TM, Taniguchi S, Ishida BY, Oka K, Can L. The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism 2000; 49: 22-31.
112. Drel VR, Mashtalir D, Ilnytska O, et al. The leptin-deficient (ob/ob) mouse. Diabetes 2006; 55: 3335-43.
113. Sivitz WI, Walsh SA, Morgan DA, Thomas MJ, Haynes WG. Effects of leptin on insulin sensitivity in normal rats. Endocrinology 1997; 138: 3395-401.
114. Madej T, Boguski MS, Bryant SH. Threading analysis suggests that the obese gene product may be a helical cytokine. FEBS Lett 1995; 373: 13-8.